Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

544 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Wellbeing of Family Carers of Adults With Intellectual Disabilities During the COVID-19 Pandemic in the UK: Longitudinal Study.
Thompson PA, Summers E, Caton S, Hayden N, Todd S, Oloidi E, Taggart L, Kelly R, Bradshaw J, Maguire R, Jahoda A, Hatton C, Hastings RP; Coronavirus and People with Learning Disabilities Study Team. Thompson PA, et al. J Intellect Disabil Res. 2024 Dec 24. doi: 10.1111/jir.13206. Online ahead of print. J Intellect Disabil Res. 2024. PMID: 39717989
Artificial Intelligence Assessment of Chest Radiographs for COVID-19.
Sasaki K, Garcia-Manero G, Nigo M, Jabbour E, Ravandi F, Wierda WG, Jain N, Takahashi K, Montalban-Bravo G, Daver NG, Thompson PA, Pemmaraju N, Kontoyiannis DP, Sato J, Karimaghaei S, Soltysiak KA, Raad II, Kantarjian HM, Carter BW; D3CODE Research Team. Sasaki K, et al. Among authors: thompson pa. Clin Lymphoma Myeloma Leuk. 2024 Nov 29:S2152-2650(24)02435-2. doi: 10.1016/j.clml.2024.11.013. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39710565
Mutant-selective AKT inhibition through lysine targeting and neo-zinc chelation.
Craven GB, Chu H, Sun JD, Carelli JD, Coyne B, Chen H, Chen Y, Ma X, Das S, Kong W, Zajdlik AD, Yang KS, Reisberg SH, Thompson PA, Lipford JR, Taunton J. Craven GB, et al. Among authors: thompson pa. Nature. 2025 Jan;637(8044):205-214. doi: 10.1038/s41586-024-08176-4. Epub 2024 Nov 6. Nature. 2025. PMID: 39506119
Correction: Statistical analysis plan for the SOLUTIONS randomised controlled trial with internal pilot: Solution Focused Brief Therapy (SFBT) in 10-17-year-olds presenting at police custody.
Thompson PA, Moody G, Coulman E, Owen-Jones E, Patel F, Gray KM, Hastings RP, Longman A, Lugg-Widger F, Segrott J, Badger J, Flynn S, Langdon PE, Playle R. Thompson PA, et al. Trials. 2024 Oct 13;25(1):675. doi: 10.1186/s13063-024-08529-4. Trials. 2024. PMID: 39396961 Free PMC article. No abstract available.
Statistical analysis plan for the SOLUTIONS randomised controlled trial with internal pilot: Solution Focused Brief Therapy (SFBT) in 10-17-year-olds presenting at policy custody.
Thompson PA, Moody G, Coulman E, Owen-Jones E, Patel F, Gray KM, Hastings RP, Longman A, Lugg-Widger F, Segrott J, Badger J, Flynn S, Langdon PE, Playle R. Thompson PA, et al. Trials. 2024 Sep 28;25(1):633. doi: 10.1186/s13063-024-08457-3. Trials. 2024. PMID: 39342238 Free PMC article.
Ending endless follow-up for low-risk CLL?
Thompson PA. Thompson PA. Blood Adv. 2024 Aug 27;8(16):4447-4448. doi: 10.1182/bloodadvances.2024012918. Blood Adv. 2024. PMID: 39190325 Free PMC article. No abstract available.
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.
Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, Lamanna N, Ma S, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes JM, McKinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar AJ, Patel MR, Seymour JF, Woyach JA, Thompson PA, Abada PB, Ho C, McNeely SC, Marella N, Nguyen B, Wang C, Ruppert AS, Nair B, Liu H, Tsai DE, Roeker LE, Ghia P. Wierda WG, et al. Among authors: thompson pa. Lancet Haematol. 2024 Sep;11(9):e682-e692. doi: 10.1016/S2352-3026(24)00172-8. Epub 2024 Jul 18. Lancet Haematol. 2024. PMID: 39033770 Clinical Trial.
Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11.
Parker GS, Toth JI, Fish S, Blanco G, Kampert T, Li X, Yang L, Stumpf CR, Steadman K, Jamborcic A, Chien S, Daniele E, Dearie A, Leriche G, Bailey S, Thompson PA. Parker GS, et al. Among authors: thompson pa. Mol Cancer Ther. 2024 Jul 5:OF1-OF13. doi: 10.1158/1535-7163.MCT-24-0219. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38967115
Discovery of Monovalent Direct Degraders of BRD4 That Act Via the Recruitment of DCAF11.
Parker GS, Toth JI, Fish S, Blanco GA, Kampert T, Li X, Yang L, Stumpf CR, Steadman K, Jamborcic A, Chien S, Daniele E, Dearie A, Leriche G, Bailey S, Thompson PA. Parker GS, et al. Among authors: thompson pa. Mol Cancer Ther. 2024 Jun 22. doi: 10.1158/1535-7163.MCT-24-0219. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38907538
544 results